Open AccessBeta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus
Author(s) -
C. Wood,
R M Wisniewski
Publication year - 1994
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.38.5.1023
Subject(s) - teicoplanin , nafcillin , cefazolin , glycopeptide , staphylococcus aureus , antibiotics , vancomycin , medicine , microbiology and biotechnology , cephalosporin , daptomycin , glycopeptide antibiotic , methicillin resistant staphylococcus aureus , staphylococcal infections , micrococcaceae , antibacterial agent , biology , penicillin , bacteria , genetics
The antibacterial efficacies of the beta-lactam antibiotics nafcillin and cefazolin were compared with those of the glycopeptide antibiotics vancomycin and teicoplanin in rats with subcutaneous abscesses infected with methicillin-susceptible Staphylococcus aureus. Animals were treated with antibiotics or diluent for 3 or 7 days. Rats receiving any antibiotic treatment, with the exception of teicoplanin-treated animals at day 7, had lower bacterial counts in their abscesses than did controls at days 3 and 7. Rats in the nafcillin and cefazolin treatment groups had lower bacterial counts in their abscesses than did rats in the vancomycin and teicoplanin treatment groups at days 3 and 7. The beta-lactam antibiotics were more effective therapy than the glycopeptide antibiotics in rats with subcutaneous abscesses infected with methicillin-susceptible S. aureus. In vitro, animal, and clinical data comparing beta-lactam and glycopeptide treatment of S. aureus infections were reviewed along with the resulting treatment recommendations.